Lin Ru, Wang Jian, Fu Wenting, Tuo Shumei, Shao Yawen
Cervical Cancer Prevention and Treatment Center, Gansu Provincial Maternity and Child-care Hospital Lanzhou 730050, Gansu, China.
Institute of Clinical Medicine, Gansu Provincial Maternity and Child-care Hospital Lanzhou 730050, Gansu, China.
Am J Transl Res. 2024 Nov 15;16(11):6745-6752. doi: 10.62347/FNVP3843. eCollection 2024.
To evaluate the efficacy of levofloxacin combined with azithromycin in the treatment of cervicitis and its effect on serum inflammatory markers.
A retrospective analysis was conducted on the clinical records of 102 patients with cervicitis treated at Gansu Provincial Maternity and Child-care Hospital between March 2022 and March 2023. The control group (47 patients) received azithromycin, while the study group (55 patients) was treated with a combination of levofloxacin and azithromycin. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) were measured before treatment and after two weeks. The efficacy, adverse reaction rate, and recurrence of cervicitis over a 6-month follow-up period were analyzed. A multiple logistic regression was performed to identify factors influencing recurrence.
Prior to treatment, no significant differences were observed between the two groups in IL-6, TNF-α, or CRP levels (all P>0.05). After treatment, both groups showed significant reductions in these markers (all P<0.0001), with the study group exhibiting more pronounced decreases (P<0.0001). The overall response rate in the study group was significantly higher than that of the control group (P=0.041). No significant difference in the incidence of adverse reactions was found between the groups (P=0.551). The recurrence rate of cervicitis was significantly higher in the control group compared to the study group (P=0.022). Logistic regression analysis identified disease severity (P=0.014, OR: 8.616; CI: 1.543-48.096), post-treatment IL-6 (P=0.003, OR: 17.573; CI: 2.720-113.531), post-treatment CRP (P=0.039, OR: 5.731; CI: 1.089-30.157), and post-treatment TNF-α (P=0.001, OR: 20.547; CI: 3.210-131.518) as independent predictors of recurrence.
Levofloxacin combined with azithromycin is more effective than azithromycin monotherapy in treating cervicitis. The combination significantly reduces inflammatory responses and recurrence rates without increasing adverse effects, making it a valuable option for clinical use.
评估左氧氟沙星联合阿奇霉素治疗宫颈炎的疗效及其对血清炎症标志物的影响。
对2022年3月至2023年3月在甘肃省妇幼保健院接受治疗的102例宫颈炎患者的临床记录进行回顾性分析。对照组(47例患者)接受阿奇霉素治疗,研究组(55例患者)接受左氧氟沙星与阿奇霉素联合治疗。在治疗前及治疗两周后检测血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和C反应蛋白(CRP)水平。分析治疗效果、不良反应发生率以及随访6个月期间宫颈炎的复发情况。进行多因素逻辑回归分析以确定影响复发的因素。
治疗前,两组患者的IL-6、TNF-α或CRP水平均无显著差异(均P>0.05)。治疗后,两组这些标志物水平均显著降低(均P<0.0001),研究组下降更为明显(P<0.0001)。研究组的总有效率显著高于对照组(P=0.041)。两组间不良反应发生率无显著差异(P=0.551)。与研究组相比,对照组宫颈炎复发率显著更高(P=0.022)。逻辑回归分析确定疾病严重程度(P=0.014,OR:8.616;CI:1.543-48.096)、治疗后IL-6(P=0.003,OR:17.573;CI:2.720-113.531)、治疗后CRP(P=0.039,OR:5.731;CI:1.089-30.157)以及治疗后TNF-α(P=0.001,OR:20.547;CI:3.210-131.518)为复发的独立预测因素。
左氧氟沙星联合阿奇霉素治疗宫颈炎比单用阿奇霉素更有效。该联合用药可显著降低炎症反应和复发率且不增加不良反应,是临床应用的一个有价值的选择。